CURRENT POSSIBILITIES FOR THE PHARMACOTHERAPY OF HEARTBURN DURING PREGNANCY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To provide a review of the data available in the current literature on the pathogenesis of heartburn during pregnancy and therapeutic possibilities of using alginates. Subject and methods. The review includes the data of foreign and Russia articles that were found in Pubmed and eLIBRARY.RU on this topic and published in the past 20 years. Results. The paper describes the physiological and pathological mechanisms of heartburn during pregnancy and the data of investigating gaviscon forte in the treatment of heartburn during pregnancy. Conclusion. Along with lifestyle and dietary modifications, the use of gaviscon forte that has demonstrated its efficacy and safety in trials covering more than 50 pregnant women is pathogenetically sound in mild and moderate heartburn.

Full Text

Restricted Access

About the authors

Varvara S. Kartseva

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: extralab@mail.ru
Junior Researcher of the Therapeutic Department Moscow 117997, Ac. Oparina str. 4, Russia

Roza M. Esayan

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: rozaes@mail.ru
PhD, head of the Therapeutic Department Moscow 117997, Ac. Oparina str. 4, Russia

Natalia A. Chukhareva

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: 0330348@gmail.com
Junior Researcher of the Therapeutic Department Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Majithia R., Johnson D.A. Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. Drugs. 2012; 72(2): 171-9.
  2. Машарова А.А., Еремина Е.Ю. Заболевания органов пищеварительной системы у беременных. Саранск; 2009. 200с.
  3. Ramu B., Mohan P., Rajasekaran M.S., Jayanthi V. Prevalence and risk factors for gastroesophageal reflux in pregnancy. Indian J. Gastroenterol. 2011; 30(3): 144-7.
  4. Ramya R.S., Jayanthi N., Alexander P.C., Vijaya S., Jayanthi V. Gastroesophageal reflux disease in pregnancy: a longitudinal study. Trop. Gastroenterol. 2014; 35(3): 168-72.
  5. Онучина Е.В., Горобец Э.А., Рожанский А.А., Цуканов В.В. Эффективность применения альгинатов в лечении изжоги у беременных. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2009; 19(6): 23-7.
  6. Raj Majithia D.A.J. Are proton pump inhibitors safe during pregnancy and lactation? Drugs. 2012; 72 (2): 171-9.
  7. Herbella F.A., Vicentine F.P., Silva L.C., Patti M.G. Postprandial proximal gastric acid pocket and gastroesophageal reflux disease. Dis Esophagus. 2012; 25(7): 652-5.
  8. Лазебник Л.Б. Изжога и гастроэзофагеальная рефлюксная болезнь: проблемы и решения. Терапевтический архив. 2008; 80(2): 5-11.
  9. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013; 108(3): 308-28; quiz 329.
  10. Чухарева Н.А., Ушкалова Е.А., Карцева В.С. Лечение изжоги у беременных. Акушерство и гинекология. 2015; 9: 110-4.
  11. Thomas E., Wade A., Crawford G., Jenner B., Levinson N., Wilkinson J. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2014; 39(6): 595-602.
  12. Rohof W.O., Bennink R.J., Smout A.J., Thomas E., Boeckxstaens G.E. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin. Gastroenterol. Hepatol. 2013; 11(12): 1585-91; quiz e1590.
  13. Sweis R., Kaufman E., Anggiansah A., Wong T., Dettmar P., Fried M. et al. Postprandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment. Pharmacol. Ther. 2013; 37(11): 1093-102.
  14. Chiu C.T., Hsu C.M., Wang C.C., Chang J.J., Sung C.M., Lin C.J. et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment. Pharmacol. Ther. 2013; 38(9): 1054-64.
  15. Poynard T., Vernisse B., Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 1998; 12(2): 159-65.
  16. Uzan M., Uzan S., Sureau C., Richard-Berthe C. Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension. Rev. Fr. Gynecol. Obstet. 1988; 83(7-9): 569-72.
  17. De Bellis I., Epifani S., Maiorino R., Tardio R. Gastroesophageal reflux in pregnancy. Giornale Ital. Ostet. Ginecol. 1999; 21(1): 17-9.
  18. Lang G.D., Dougall A. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy. Br. J. Clin. Pract. 1989; 66(Suppl.): 48-51; discussion 61-4.
  19. Lindow S.W., Regnell P., Sykes J., Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int. J. Clin. Pract. 2003; 57(3): 175-9.
  20. Strugala V., Bassin J., Swales V.S., Lindow S.W., Dettmar P.W., Thomas E.C. Assessment of the safety and efficacy of a raft-forming alginate reflux suppressant (Liquid Gaviscon) for the treatment of heartburn during pregnancy. ISRN Obstet. Gynecol. 2012; 2012: 481870.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies